AbbVie said on May 9, 2025 it expanded the Board from fourteen directors to fifteen and appointed Thomas J. Falk as a Class III director, assigning him to the Audit Committee.

1. 01

   AbbVie said on May 9, 2025 it expanded the Board from fourteen directors to fifteen and appointed Thomas J. Falk as a Class III director, assigning him to the Audit Committee.

2. 02

   The company said the Board size will decrease from fifteen directors to thirteen directors when Richard A. Gonzalez and Glenn F. Tilton retire from the Board on July 1, 2025.

3. 03

   The company said the Compensation Committee approved a change to Robert A. Michael's compensation on May 8, 2025 to reflect his role as Chairman, and that his annual bonus target for 2025 will be 165% of his base salary.

4. 04

   The company said stockholders did not approve, at its annual meeting on May 9, 2025, the management proposal to amend the certificate of incorporation to eliminate supermajority voting or the stockholder proposal to implement simple majority voting.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.